STOCK TITAN
  1. Home
  2. News
  3. MNOV

Medicinova, Inc. - MNOV STOCK NEWS

Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.

Medicinova, Inc. (NASDAQ: MNOV), headquartered in La Jolla, California, is a clinical-stage biopharmaceutical company focused on acquiring and developing promising small-molecule therapeutics to treat diseases with unmet medical needs. Specializing in therapies for neurological disorders and fibrotic diseases, Medicinova has a strategic emphasis on the U.S. market.

Medicinova’s robust product portfolio includes several innovative drugs in late-stage clinical development. These include MN-001 (tipelukast) and MN-166 (ibudilast), both of which boast multiple mechanisms of action and strong safety profiles. MN-166 (ibudilast) is in Phase 3 clinical trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). It is also being evaluated in Phase 2 trials for Long COVID, substance dependence, and other neurodegenerative diseases.

The company recently received a series of new patents, significantly extending its intellectual property protection. One such patent covers the use of MN-166 for treating macular injury and decreasing macular volume loss associated with progressive multiple sclerosis. Another patent covers the formulation of MN-166 in extended-release oral forms, which is expected to improve patient compliance and reduce side effects.

Medicinova has demonstrated the potential of MN-166 in ophthalmic neurodegenerative diseases, supported by positive data from various animal model studies and the SPRINT-MS Phase 2b trial. Additionally, MN-166 is under investigation for its efficacy in treating glioblastoma, Long COVID, chemotherapy-induced peripheral neuropathy (CIPN), and substance use disorder.

Alongside its development efforts, Medicinova has a strong track record of securing investigator-sponsored clinical trials funded through government grants. This financial support underscores the promise and potential of its therapies to address critical medical needs.

For more information or investor inquiries, please contact Geoff O'Brien, Vice President at info@medicinova.com.

News

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Rhea-AI Summary
MediciNova, Inc. has received a Notice of Grant from the Chinese Patent Office for a new patent covering MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than April 2040 and covers a wide range of doses, dosing frequencies, and treatment periods. The Chief Medical Officer commented on the potential of MN-166 in ophthalmic neurodegenerative diseases and the positive data from previous studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
none
-
News

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) announced the selection of an abstract for a poster presentation at the Society of Toxicology 63rd Annual Meeting and ToxExpo, detailing the results of a nonclinical study of MN-166 (ibudilast) in chlorine gas-induced acute lung injury. The study will be presented by collaborator Perenlei Enkhbaatar, MD, PhD, FAHA, and funded in part by the Department of Health and Human Services.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
none
-
News

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) has received a Notice of Decision to Grant from the European Patent Office for a pending patent application covering the combination of MN-166 (ibudilast) and interferon-beta for the treatment of progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039 and covers a wide range of doses, dosing durations, and frequencies for the combination. The company's Chief Medical Officer believes this new patent could increase the potential value of MN-166, indicating a synergistic effect of the combination in reducing the risk of disability progression.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.17%
Tags
none
News

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Rhea-AI Summary
MediciNova, Inc. (NASDAQ:MNOV) announced positive results from a Phase 2 clinical trial of MN-166 (ibudilast) in glioblastoma (GBM) patients. The trial evaluated the combination of MN-166 and anti-PD1 or anti-PD-L1 therapy in GBM models. The primary endpoints were safety, tolerability, and efficacy. MN-166 and TMZ combination treatment was safe and well-tolerated, with a PFS6 rate of 44% for new GBM and 31% for recurrent GBM. Preclinical studies showed that adding MN-166 to anti-PD1 or anti-PD-L1 therapy significantly extended survival. Chief Medical Officer, Kazuko Matsuda, expressed excitement for the findings and future trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.73%
Tags
clinical trial
-
News

MediciNova’s Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Rhea-AI Summary
MediciNova announces first patient treated in clinical trial for SAR444836 gene therapy for PKU
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
clinical trial
-
News

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Rhea-AI Summary
MediciNova receives Notice of Allowance for ALS treatment patent
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

MediciNova Receives Gene Therapy Milestone Payment

Rhea-AI Summary
MediciNova receives $1 million milestone payment from Genzyme Corporation
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none
-
News

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Rhea-AI Summary
MediciNova announces positive results from nonclinical studies on MN-166 as a potential treatment for chlorine gas-induced lung damage. MN-166 high dose showed a significant improvement in pulmonary function, with a 46% higher PaO2/FiO2 ratio compared to the negative control group. MN-166 has potential to treat acute lung disease from various causes. No efficacy results from the second nonclinical model study. Meeting with FDA planned for next steps.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
none
-
News

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Rhea-AI Summary
MediciNova, Inc. announced that an abstract on tumor tissue analysis data from a clinical trial of MN-166 in glioblastoma has been selected for poster presentation at the 28th Annual Meeting of the Society for Neuro-Oncology. The poster will be presented by Dr. Justin Lathia, and the session is scheduled for November 17, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Rhea-AI Summary
MediciNova, Inc. has received a Notice of Intention to Grant from the European Patent Office for a pending patent application that covers MN-166 (ibudilast) for the treatment of macular injury associated with progressive multiple sclerosis. The patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 in treating macular injury and decreasing macular volume loss associated with progressive multiple sclerosis. The patent also covers a wide range of doses and dosing frequencies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.48%
Tags
none

FAQ

What is the current stock price of Medicinova (MNOV)?

The current stock price of Medicinova (MNOV) is $2.02 as of January 29, 2025.

What is the market cap of Medicinova (MNOV)?

The market cap of Medicinova (MNOV) is approximately 98.1M.

What is Medicinova, Inc.?

Medicinova, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapeutics for diseases with unmet medical needs, especially in the fields of neurology and fibrotic diseases.

What are the key areas of focus for Medicinova?

Medicinova focuses on developing therapies for neurological disorders and fibrotic diseases, especially for the U.S. market.

What are the main products in Medicinova's pipeline?

Medicinova's pipeline includes MN-001 (tipelukast) and MN-166 (ibudilast), which are in late-stage clinical development for various neurodegenerative and inflammatory diseases.

What is MN-166 (ibudilast)?

MN-166 (ibudilast) is a small molecule compound that inhibits phosphodiesterase type-4 (PDE4) and inflammatory cytokines. It is being developed for ALS, progressive MS, glioblastoma, Long COVID, CIPN, and substance use disorder.

What recent achievements has Medicinova made?

Medicinova recently received several new patents, including those covering MN-166 for treating progressive multiple sclerosis and extended-release formulations, enhancing the potential value and patient compliance of its therapies.

What financial backing does Medicinova have?

Medicinova has a strong record of securing investigator-sponsored clinical trials funded through government grants, highlighting the promise and potential of its therapies.

How does MN-166 (ibudilast) work?

MN-166 (ibudilast) works by inhibiting phosphodiesterase type-4 (PDE4) and inflammatory cytokines, which are involved in multiple neurodegenerative and inflammatory processes.

What is the significance of Medicinova's new patents?

The new patents significantly extend the intellectual property protection for MN-166, covering its use in various diseases and formulations, which can increase the drug's potential value and patient compliance.

Where is Medicinova headquartered?

Medicinova is headquartered in La Jolla, California.

How can investors contact Medicinova?

Investors can contact Geoff O'Brien, Vice President of Medicinova, Inc., via email at info@medicinova.com.
Stock MNOV logo
Medicinova, Inc.

Nasdaq:MNOV

MNOV Rankings

#4446 Ranked by Market Cap
N/A Ranked by Dividends

MNOV Stock Data

98.09M
47.58M
2.98%
21.3%
0.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
LA JOLLA